Article Text

Response to ‘Detection of myositis-specific antibodies: additional notes’
  1. Maria Infantino1,
  2. Mariangela Manfredi1,
  3. Valentina Grossi1,
  4. Maurizio Benucci2
  1. 1Laboratory of Immunology and Allergology, S. Giovanni di Dio Hospital, Florence, Italy
  2. 2Rheumatology Unit, S. Giovanni di Dio Hospital, Florence, Italy
  1. Correspondence to Dr Maria Infantino, Laboratory of Immunology and Allergology, Ospedale San Giovanni di Dio, Florence 55100, Italy; maria2.infantino{at}

Statistics from

With great interest, we read the letters that have commented on the recent European League Against Rheumatism/American College of Rheumatology classification criteria for idiopathic inflammatory myopathies1 (IIMs) and ensuing discussions.2 3 This highlights how harmonising myositis-specific antibodies (MSA) testing methodologies is currently a hot topic of debate among laboratory specialists, clinicians and manufacturers.

I would particularly like to share our own immunology laboratory experience by expanding on the letter entitled ‘Detection of myositis-specific antibodies: additional notes’ by M Mahler and M Fritzler4 with which we wholly agree.

Newer technologies, such as line immunoassays (LIA) and dot blots (DB), which provide greater sensitivity and rapid serological diagnoses, have standardisation and specificity drawbacks, but the tight connection between autoantibodies and clinical phenotypes underline a great need …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles